VORICONAZOLE

Drug #2320

Voriconazole is a triazole antifungal agent. Voriconazole is designated chemically as (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoro-4 pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol. It is available as a lyophilized powder for solution for intravenous infusion, film-coated tablets for oral administration, and as a powder for oral suspension.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to phenylpropylamines.

It is also classified under Antifungals .

Molecular Weight: 349.31 · Non-proprietary name: VORICONAZOLE.

Pharmacokinetics

Absorption: VORICONAZOLE has an oral bioavailability is 96%.

Distribution: VORICONAZOLE has a volume of distribution is 4.6L/kg. plasma protein binding is 58%.

Elimination: it is metabolised via Hepatic, renal excretion is less than 2% by urine.

Indications

VORICONAZOLE is primarily indicated in conditions like candidemia, Candidiasis, Invasive aspergillosis.

Contraindications

None recorded.

Dosage

VORICONAZOLE's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
0 – 6 mg/kg	—	Every 2h	IV
100 mg	100 mg	Every 2h	PO	less than 40 kg)
200 mg	200 mg	Every 2h	PO	(40 kg or more)
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

206 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

VORICONAZOLE is known to cause more or less tolerable side effects which are usually transient. These include Chills, Fever, Hallucination , Headache, Nausea, Rash, Tachycardia, Visual disturbances, Vomiting .

Warnings / Precautions

Hepatic Toxicity: Serious hepatic reactions reported. Evaluate liver function tests at start of and during voriconazole therapy. Visual Disturbances (including optic neuritis and papilledema): Monitor visual function if treatment continues beyond 28 days. Embryo-Fetal Toxicity: Do not administer to pregnant women unless the benefit to the mother outweighs the risk to the fetus. Inform pregnant patient of hazard. Patients with Hereditary Galactose Intolerance Lapp Lactase Deficiency or Glucose-Galactose Malabsorption: Do not use. Arrhythmias and QT Prolongation: Correct potassium, magnesium and calcium prior to use; caution patients with proarrhythmic conditions. Infusion Related Reactions (including anaphylaxis): Stop the infusion. Dermatological Reactions: Discontinue for exfoliative cutaneous reactions or phototoxicity. Avoid sunlight due to risk of photosensitivity.Skeletal Events: Fluorosis and periostitis with long-term voriconazole therapy. Discontinue if these events occur

Interference in Pathology

VORICONAZOLE may interfere in the diagnosis of Liver Function Test (LFT) .

Available Brands

Click on a strength to view available brands.

Single Ingredient

Tabs

200 mg 40 mg

Storage Conditions

VORICONAZOLE should be stored Injection. Tablet. Powder for Oral Suspension.

Drug Classification

1.6.3 — Antifungal drugs

Manufacturers

Manufacturers of VORICONAZOLE in Pakistan:

Ferozson